|Slideshows|September 26, 2017

A New Drug in Development for Negative Symptoms

Is an effective, well-tolerated treatment for the negative symptoms of schizophrenia on the horizon?

View the slides in PDF format.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

ByAmit Etkin, MD, PhD

June 9th 2026

Paying Attention to the Psychopharmacology Pipeline

ByMike Hennessy Jr

June 9th 2026

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

ByLeighann Forbes, PhD

June 8th 2026

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

ByJoseph F. Goldberg, MD,Robert M. Post, MD

June 5th 2026

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

ByLeah Kuntz

June 4th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

A New Drug in Development for Negative Symptoms

Related Content

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

Paying Attention to the Psychopharmacology Pipeline

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

Paying Attention to the Psychopharmacology Pipeline

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings